Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06937619 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 263
- Enrollment target
NCT06937619 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 263 participants.
The verdict
NCT06937619, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 263 participants
- Enrollment target
Study Summary
This study will assess the pharmacokinetics and relative Bioavailability of risankizumab following subcutaneous (SC) administration with on-body Injector in Healthy Adult Participants.
Interventions
- DRUG Risankizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2025-04-21 |
| Est. Completion | 2025-11-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06937619
The ClinicalTrials.gov registry entry for NCT06937619 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 263 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Risankizumab is the first listed.
NCT06937619 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06937619 about?
NCT06937619 is a clinical study titled "A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants". This study will assess the pharmacokinetics and relative Bioavailability of risankizumab following subcutaneous (SC) administration with on-body Injector in Healthy Adult Participants.
What is the current status of trial NCT06937619?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 263 participants. The study started on 2025-04-21. Estimated completion is 2025-11-10.
What interventions are being tested in trial NCT06937619?
The interventions under investigation include: Risankizumab (DRUG).
Who is sponsoring clinical trial NCT06937619?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.